Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLOD2 | O00469 | 3/20 | 0.39 |
| ▸ | PLOD3 | O60568 | 2/20 | 0.38 |
| ▸ | PLOD1 | Q02809 | 2/20 | 0.38 |
| ▸ | FAAH | O00519 | 8/20 | 0.36 |
| ▸ | CES1 | P23141 | 6/20 | 0.34 |
| ▸ | CES2 | O00748 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27628030 | 0.82 | PLOD2 (0.44) | PLOD2PLOD3PLOD1FAAHCES1 | |
| SCHEMBL9823683 | 0.82 | HSD17B10 (0.41) | PLOD2PLOD3PLOD1FAAHCES1 | |
| SCHEMBL197340 | 0.81 | MGAM (0.48) | PLOD2PLOD3PLOD1FAAHCES1 | |
| SCHEMBL18643782 | 0.81 | PLOD2 (0.38) | PLOD2PLOD3PLOD1FAAHCES1 | |
| SCHEMBL27482451 | 0.79 | PLOD2 (0.36) | PLOD2PLOD3PLOD1FAAHCES1 | |
| SCHEMBL183178 | 0.78 | PLOD2 (0.46) | PLOD2PLOD3PLOD1FAAHCES1 | |
| Water SCHEMBL7191917 | 0.76 | PLOD2 (0.44) | PLOD2PLOD3PLOD1FAAHCES1 | |
| SCHEMBL9326020 | 0.76 | PLOD2 (0.44) | PLOD2PLOD3PLOD1FAAHCES1 | |
| SCHEMBL6517983 | 0.76 | PLOD2 (0.44) | PLOD2PLOD3PLOD1FAAHCES1 | |
| SCHEMBL7213763 | 0.76 | PLOD2 (0.44) | PLOD2PLOD3PLOD1FAAHCES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117730073-A | Serotonin 5-HT2A, 5-HT2B and 5-HT2C receptor inverse agonists | 东北大学 | 2024-03-19 | — | — | CN | disclosed |
| US-7498433-B2 | Process and intermediates for the preparation of olanzapine | KRKA, TOVARNA ZDRAVIL, D.D. (SI) | 2009-03-03 | — | — | US | disclosed |
| EP-1594879-B1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF OLANZAPINE | KRKA TOVARNA ZDRAVIL D D NOVO (SI) | 2008-10-22 | — | — | EP | disclosed |
| US-20060040921-A1 | Process and intermediates for the preparation of olanzapine | KRKA, TOVARNA ZDRAVIL D.D. (SI) | 2006-02-23 | — | — | US | disclosed |
| EP-1594879-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF OLANZAPINE | KRKA, tovarna zdravil, d.d., Novo mesto (SI) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004065390-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF OLANZAPINE | KRKA, TOVARNA ZDRAVIL, D.D., NOVO MESTO (SI) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040921-A1 | Process and intermediates for the preparation of olanzapine | CYP4F11, CYP4A11, CYP3A4 | PLOD2 4810/4885PLOD3 4884/4885PLOD1 4744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.